- Home
- RVI vs PACB Comparison
RVI vs PACB Comparison
Compare RVI & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.2M | 696.3M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RVI | PACB |
|---|---|---|
| Price | $21.04 | $1.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $2.78 |
| AVG Volume (30 Days) | 205.1K | ★ 12.3M |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $18.00 | $1.07 |
| 52 Week High | $77.39 | $3.44 |
Technical Indicators
Market Signals| Indicator | RVI | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 42.80 |
| Support Level | $18.00 | $1.27 |
| Resistance Level | $29.72 | $3.07 |
| Average True Range (ATR) | 1.09 | 0.31 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 45.48 | 11.07 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.